XP21279 ( DrugBank: - )

---

1 disease

ID	Disease name (Link within this page)	Number of trials
6	Parkinson disease	2

6. Parkinson disease

---

Clinical trials : 2,298 /  Drugs : 2,202 - (DrugBank : 350) / Drug target genes : 188 - Drug target pathways : 202

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01171313 (ClinicalTrials.gov)	July 2010	26/7/2010	A Efficacy, Safety and Pharmacokinetic Study of XP21279 and Sinemet® in Parkinson's Disease Subjects	A Phase 2 Efficacy, Safety and Pharmacokinetic Study of XP21279 BL2 and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations	Parkinson's Disease	Drug: XP21279 and carbidopa (experimental);Drug: Sinemet (comparator);Drug: Placebo for XP21279 and carbidopa;Drug: Placebo for Sinemet	XenoPort, Inc.	NULL	Completed	30 Years	80 Years	All	35	Phase 2	United States
2	NCT00914602 (ClinicalTrials.gov)	May 2009	3/6/2009	An Exploratory Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects	An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn®) and Sinemet® in Parkinson's Disease Subjects With Motor Fluctuations	Parkinson's Disease	Drug: Sinemet 25-100 Oral Tablet;Drug: XP21279;Drug: Carbidopa Pill	XenoPort, Inc.	NULL	Completed	30 Years	75 Years	All	14	Phase 1/Phase 2	United States